Last edition
News about "HES therapy"
AstraZeneca Wins US FDA Approval for Fasenra in Hypereosinophilic Syndrome
AstraZeneca receives US Food and Drug Administration (FDA) approval for Fasenra to treat hypereosinophilic syndrome, supported by positive phase 3 NATRON trial results.
HES Therapy | 16/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members